Phase II Trial of Amivantamab with Hyaluronidase vs. Cetuximab for Advanced Skin Cancer
A phase II trial is comparing amivantamab with hyaluronidase to cetuximab for advanced cutaneous squamous cell carcinoma.
Asset / Drug
Drug and asset intelligence for Amivantamab with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A clinical trial has been initiated to evaluate the efficacy of amivantamab in combination with lazertinib or platinum-based chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.